Quick answer: latest quarter results, by ticker or company name

Reported Q: Q4 2023 Rev YoY: +9.3% EPS YoY: +17.9% Move: -1.48%

Vertex Pharmaceuticals

VRTX

$470.87 -1.48%

Exchange NASDAQ Sector Healthcare Industry Biotechnology

Q4 2023

Published: Feb 15, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for VRTX

Reported

Report Date

Feb 15, 2024

Quarter Q4 2023

Revenue

2.52B

YoY: +9.3%

EPS

3.71

YoY: +17.9%

Market Move

-1.48%

Previous quarter: N/A

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $2.52B up 9.3% year-over-year
EPS of $3.71 increased by 17.9% from previous year
Gross margin of 85.4%
Net income of 968.80M
""We've delivered another excellent quarter to finish 2023, established a strong foundation for continued growth, and started off 2024 with tremendous momentum with additional approvals for CASGEVY, positive Phase 3 results for VX-548 in acute pain," - Reshma Kewalramani, CEO." - Reshma Kewalramani

VRTX

Vertex Pharmaceuticals Incorporated

Period Q4 2023

Currency USD

Report Type Quarterly Earnings

Generated Feb 10, 2026

Executive Summary

Vertex Pharmaceuticals reported exemplary results for Q4 2023 with revenues reaching $2.52 billion, an increase of 9% compared to Q4 2022, driven primarily by strong demand for TRIKAFTA and new product launches such as CASGEVY. The company achieved $9.87 billion in total revenue for the year, marking an 11% growth from 2022. This financial performance reflects an ongoing trend of double-digit growth for the ninth consecutive year, highlighting robust market positioning amid a favorable regulatory environment and ongoing innovation in their drug portfolio. Management indicated a strong outlook entering 2024, with foundational growth anticipated driven by new therapies and an expanding patient base in cystic fibrosis and pain management treatments.

Key Performance Indicators

Revenue

Increasing

2.52B

QoQ: 1.38% | YoY: 9.34%

Gross Profit

Increasing

2.15B

85.38% margin

QoQ: -0.70% | YoY: 6.45%

Operating Income

Decreasing

958.80M

QoQ: -7.64% | YoY: -7.23%

Net Income

Increasing

968.80M

QoQ: -6.42% | YoY: 18.31%

EPS

Increasing

3.76

QoQ: -6.23% | YoY: 17.87%

Revenue Trend

Margin Analysis

Financial Highlights

- Revenue: $2.52 billion in Q4 2023, up 9% YoY
- Net Income: $968 million, reflecting a net income margin of 38.4%
- EPS: $4.20, a 12% increase YoY
- Operating Income: $1.15 billion, stable compared to Q4 2022
- Cash and Investments: $13.7 billion, showcasing strong liquidity position
- Debt-to-Equity Ratio: 0.046, indicating a very low leverage situation
Management emphasized a significant growth trajectory within cystic fibrosis, with revenues from CF products totaling $9.87 billion for the year, fueled by the new market introduction of CASGEVY, which is widely anticipated to expand treatment options and patient reach.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	2.52B	9.34%	1.38%
Gross Profit	2.15B	6.45%	-0.70%
Operating Income	958.80M	-7.23%	-7.64%
Net Income	968.80M	18.31%	-6.42%
EPS	3.76	17.87%	-6.23%

Key Financial Ratios

Gross Profit Margin

Excellent

85.40%

Gross profit margin is exceptional, indicating strong pricing power and operational efficiency

Operating Profit Margin

Excellent

38.10%

Operating margin is exceptional, indicating strong pricing power and operational efficiency

Net Profit Margin

Excellent

38.50%

Net profit margin is exceptional, indicating strong pricing power and operational efficiency

Return on Assets

Fair

4.26%

Return on assets is acceptable but below top-tier companies

Return on Equity

Fair

5.51%

Return on equity is acceptable but below top-tier companies

Current Ratio

Strong

3.99

Current ratio indicates excellent liquidity and financial flexibility

Debt to Equity

Conservative

0.05

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Growth

27.06x

Elevated P/E suggests growth expectations or premium valuation

Price to Book

Premium

5.96x

Trading at premium to book value, reflects strong intangibles or growth

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q4 2024	2,912.00	3.50	+15.7%	View
Q3 2024	2,771.90	4.01	+11.6%	View
Q2 2024	2,634.70	-13.92	+5.7%	View
Q1 2024	2,687.20	4.21	+13.2%	View
Q4 2023	2,517.70	3.71	+9.3%	View

VRTX

Vertex Pharmaceuticals

Q4 2024 Report

Vertex Pharmaceuticals Incorporated (VRTX) Q4 2024 Financial Results: Record Revenue Growth and Strategic Diversification...

Read full report

VRTX

Vertex Pharmaceuticals

Q3 2024 Report

Vertex Pharmaceuticals Q3 2024 Results: Strong Performance and New Opportunities...

Read full report

VRTX

Vertex Pharmaceuticals

Q2 2024 Report

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2024 Financial Results: Strong Revenue Growth Offset by Strategic Expenses...

Read full report

VRTX

Vertex Pharmaceuticals

Q1 2024 Report

Vertex Pharmaceuticals Incorporated (VRTX) Q1 2024 Results: Strong Growth, Strategic Expansion in CF and Pain Management...

Read full report

Vertex Pharmaceuticals (VRTX) Q4 2023 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More VRTX Quarterly Reports

VRTX

VRTX

VRTX

VRTX

Q4 2023 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

VRTX Full Profile

VRTX Financial Statements

Earnings Calendar